Nektar Meets Failure Again, This Time In Phase II Lupus Study

 
• By Alaric DeArment

Nektar, which had multiple trial failures for cancer drug bempegaldesleukin last year, and Lilly will now focus on rezpegaldesleukin in atopic dermatitis. Nektar is planning significant cost reductions.

Nektar said the Phase II study of rezpeg in SLE failed • Source: Shutterstock

More from Clinical Trials

More from R&D